Overview Open-Label Extension Study of Trofinetide for Rett Syndrome Status: Enrolling by invitation Trial end date: 2023-01-01 Target enrollment: Participant gender: Summary To investigate the safety and tolerability of continued long-term treatment with oral trofinetide in girls and women with Rett syndrome Phase: Phase 3 Details Lead Sponsor: ACADIA Pharmaceuticals Inc.